Mark Stephen Katz, Executive Vice President and General Counsel at Ryan Specialty Holdings, Inc. (NASDAQ:RYAN), recently increased his personal stake in the company. On June 3, 2026, Mr. Katz acquired shares of Ryan Specialty Class A Common Stock, totaling an investment valued at approximately $99,888.
The details of this transaction indicate that Mr. Katz purchased 3,215 individual shares. The acquisition spanned a narrow price range, from $31.0550 to $31.0694 per share. Based on these purchase prices, the weighted average cost for the shares was determined to be $31.0694 per share. Following this reported transaction, Mr. Katz's direct holdings of Ryan Specialty Holdings, Inc. Class A Common Stock now amount to 4,332 shares.
This insider buying activity comes against a backdrop where the company's stock is trading close to its 52-week low of $29.28, representing a decline of 55% over the past year. Despite this price movement, external valuation metrics suggest potential undervaluation. Specifically, an analysis provided by InvestingPro estimates the Fair Value of the stock at $42.36, suggesting it may present as an undervalued investment opportunity within the current market landscape.
Further supporting the case for potential value, an InvestingPro tip noted that five separate analysts have recently revised their earnings estimates upwards for the upcoming period. Investors seeking a more comprehensive understanding of the company's financial standing can access additional insights through the platform’s Pro Research Report, which includes seven other ProTips.
In addition to the insider transaction and valuation data, Ryan Specialty Group also announced significant corporate actions concerning its capital structure. The group reported an increase in its share repurchase program by $300 million. This action elevates the total available amount for buybacks to $300 million. This fresh authorization follows the previous use of a $300 million allowance, which was depleted after repurchasing $260 million worth of Class A common stock during the second quarter.
Analyst coverage remains varied and highlights differing views on the company's future trajectory. Keefe, Bruyette & Woods adjusted its recommendation for Ryan Specialty shares, raising its price target from $42 to $44 while maintaining an Outperform rating. This firm also modified its earnings per share projections for both 2026 and 2027, specifically incorporating anticipated effects of the company's share buybacks.
In contrast, Wells Fargo issued a downgrade, moving Ryan Specialty from Overweight to Equal Weight. The rationale provided by the bank cited a weaker growth outlook, resulting in a reduction of the price target to $31. Separately, Mizuho lowered its price target to $35, down from $42$, while maintaining a Neutral rating. This adjustment was attributed to revised guidance for fiscal year 2026, which now anticipates mid-single-digit organic growth.
These multiple developments paint a picture of strategic financial management by the company, coupled with a spectrum of expert opinion regarding Ryan Specialty’s future performance and valuation.